TRACON to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 10, 2022
July 27, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
July 26, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 02, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022 16:02 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON to Report First Quarter 2022 Financial Results and Corporate Update on May 11, 2022
May 04, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, May 04, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K.
April 19, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, April 19, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals to Present at the Maxim Group 2022 Virtual Growth Conference
March 23, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
March 15, 2022 16:02 ET
|
TRACON Pharmaceuticals, Inc.
Announced FDA Approval of Amended ENVASARC Protocol, ENVASARC Interim Efficacy Data on Track for 2H22Initiating combination trial of proprietary CTLA-4 with envafolimab in 2022 SAN...
TRACON Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 11, 2022 08:05 ET
|
TRACON Pharmaceuticals, Inc.
SAN DIEGO, March 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...